Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy.
Lian X, Seiger KW, Parsons EM, Gao C, Sun W, Gladkov GT, Roseto IC, Einkauf KB, Osborn MR, Chevalier JM, Jiang C, Blackmer J, Carrington M, Rosenberg ES, Lederman MM, McMahon DK, Bosch RJ, Jacobson JM, Gandhi RT, Peluso MJ, Chun TW, Deeks SG, Yu XG, Lichterfeld M. Lian X, et al. Among authors: lederman mm. Cell Host Microbe. 2023 Jan 11;31(1):83-96.e5. doi: 10.1016/j.chom.2022.12.002. Epub 2023 Jan 2. Cell Host Microbe. 2023. PMID: 36596305 Free PMC article.
A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3).
Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, Arakaki R, Snyder S, Coombs RW, Bosch RJ, Spritzler J, Chernoff M, Aga E, Myers L, Schock B, Lederman MM. Wallis RS, et al. Among authors: lederman mm. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):281-6. doi: 10.1097/00126334-200303010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 12626887 Clinical Trial.
Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors.
Wu H, Mellors J, Ruan P, McMahon D, Kelleher D, Lederman MM; CNAA2004 Study Investigators. Wu H, et al. Among authors: lederman mm. J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):557-63. doi: 10.1097/00126334-200308150-00002. J Acquir Immune Defic Syndr. 2003. PMID: 12902798 Clinical Trial.
Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.
Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC Jr, Glesby MJ; National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Jacobson JM, et al. Among authors: lederman mm. J Infect Dis. 2003 Dec 15;188(12):1804-14. doi: 10.1086/379899. Epub 2003 Dec 9. J Infect Dis. 2003. PMID: 14673758 Clinical Trial.
Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection.
Martin MP, Lederman MM, Hutcheson HB, Goedert JJ, Nelson GW, van Kooyk Y, Detels R, Buchbinder S, Hoots K, Vlahov D, O'Brien SJ, Carrington M. Martin MP, et al. Among authors: lederman mm. J Virol. 2004 Dec;78(24):14053-6. doi: 10.1128/JVI.78.24.14053-14056.2004. J Virol. 2004. PMID: 15564514 Free PMC article.
423 results